QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 td-cowen-maintains-buy-on-insmed-raises-price-target-to-231

TD Cowen analyst Ritu Baral maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $223 to $231.

 insmed-wins-eu-approval-for-brinsupri-the-first-treatment-for-non-cystic-fibrosis-bronchiectasis-in-patients-12-years-of-age-and-older-with-two-or-more-exacerbations-in-the-prior-12-months

— Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damage —— BR...

 druckenmiller-opens-position-in-amazon-closes-microsoft--heres-more-of-duquesnes-biggest-q3-moves

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven...

 wells-fargo-maintains-overweight-on-insmed-raises-price-target-to-217

Wells Fargo analyst Tiago Fauth maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $171 to $217.

 goldman-sachs-maintains-buy-on-insmed-raises-price-target-to-225

Goldman Sachs analyst Andrea Tan maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $196 to $225.

 ubs-maintains-buy-on-insmed-raises-price-target-to-223

UBS analyst Trung Huynh maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $194 to $223.

 rbc-capital-maintains-outperform-on-insmed-raises-price-target-to-215

RBC Capital analyst Leonid Timashev maintains Insmed (NASDAQ:INSM) with a Outperform and raises the price target from $139 t...

 meta-tumbles-10-google-marks-historic-rally-whats-moving-markets-thursday

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the me...

 insmed-raises-fy2025-global-arikayce-sales-guidance-from-405m-425m-to-420m-430m

Balance Sheet, Financial Guidance, and Planned InvestmentsAs of September 30, 2025, Insmed had cash, cash equivalents, and mark...

 insmed-q3-eps-175-misses-138-estimate-sales-142342m-beat-115604m-estimate

Insmed (NASDAQ:INSM) reported quarterly losses of $(1.75) per share which missed the analyst consensus estimate of $(1.38) by 2...

 a-preview-of-insmeds-earnings
A Preview Of Insmed's Earnings
10/29/2025 18:01:52

 b-of-a-securities-maintains-buy-on-insmed-raises-price-target-to-187

B of A Securities analyst Jason Zemansky maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $142 to ...

 insmed-to-present-six-abstracts-from-phase-3-aspen-study-of-brinsupri-at-chest-2025

—Data on Structural Lung Changes from a High-Resolution CT Substudy to be Presented as Late-Breaker——Additional Analyses Will H...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION